Kintor Pharmaceutical Receives China Patent Grant Notice for KT-939

• Kintor Pharmaceutical received notice of a Chinese invention patent grant for KT-939 on October 21, 2026.
• Patent registration formalities remain in progress for the tyrosinase inhibitor, which reduces melanin production.
• KT-939 is the company’s core commercialized product, targeting the high-end cosmetic raw material market for skin whitening and freckle removal.
• Complete registration materials for KT-939 as a functional cosmetic raw material were submitted to China’s drug regulator on September 18, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261021-12378550), on October 21, 2026, and is solely responsible for the information contained therein.